🇺🇸 FDA
Pipeline program

MK-8591A

MK-8591A-033

Phase 3 small_molecule active

Quick answer

MK-8591A for HIV infection is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
HIV infection
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials